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Enteral cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral 
nutrition: a randomized, placebocontrolled, cross-over study !
Rob MacLaren, Jane M. Gervasio, David A. Kuhl, Teresa N. Livingston, D. Kyle Swift, Roland 
N. Dickerson, Rex O. Brown, A. Stacey Headley, Kenneth A. Kudsk, John J. Lima !!
Purpose: To evaluate the comparative efficacies of enteral cisapride (CIS), erythromycin (ERY), 
metoclopramide (MET), and placebo (PLA) for promotion of gastric emptying in critically ill 
patients intolerant to gastric enteral nutrition (EN). 
!
Methods: Ten critically ill patients with an aspirated gastric residual volume (GRV) greater than 
150 ml receiving EN were administered a single enteral dose of CIS 10 mg, ERY 200 mg, MET 
10 mg, and PLA (water) every 12 hours in a randomized, cross-over manner. Acetaminophen 
solution (1 g) was administered concurrently with each dose to evaluate gastric emptying. GRVs 
were assessed and plasma acetaminophen concentrations were serially determined by TDx 
between 0 and 12 hours. Compartmental pharmacokinetic methods were used to calculate 
absorption lag time (thg), mean residence time of absorption (MRTabs), time to peak 
concentration (tP), elimination rate constant (k), and area under the plasma concentration- time 
curve (AUC). Statistical analysis included ANOVA and post hoc comparison using Fisher's LSD. 
!
Results: GRVs during the study were not significantly different between agents. Pharmacokinetic 
parameters (mean ± SD) varied as follows: 
Agent (n) tLag (min) MRTabs (min) tP (min)  k (1/min × 10-2)  AUC (mg/L/min) 
CIS (6)  20.8 ± 16.5 4.6 ± 3.6 * 23.1 ± 0.6*+ 0.766 ± 0.493  1774 ± 1190 
ERY (8)  13.1 ± 18.3 28.1 ± 26.6 65.2 ± 26.8 0.839 ± 0.539  2306 ± 1253 
MET (8)  7.9 ± 14.6 8.6 ± 12.7* 39.8 ± 9.8*+ 0.847 ± .0451  2255 ± 1472 
PLA (8)  12.5 ± 18.1 20.5 ± 17.8 69.2 ± 13.4 0.650 ± 0.230  2582 ± 1586 
*p < 0.05 versus ERY; +p < 0.05 versus PLA !
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Conclusions: In critically ill patients intolerant to enteral nutrition, a single enteral dose of 
cisapride or metoclopramide significantly accelerated gastric emptying compared to 
erythromycin and placebo. Erythromycin provided no advantage over placebo.
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